HistoSonics, the developer of the Edison Histotripsy System and pioneer of the world’s first non-invasive histotripsy therapy platform, has closed an oversubscribed $250 million growth financing round. The funding, led by the company’s new ownership group and joined by prominent investors including Thiel Bio, Founders Fund, K5 Global, Bezos Expeditions, and Wellington Management, positions HistoSonics to expand its global presence and pursue new therapeutic applications across the body.
This latest round follows the $2.25 billion majority stake acquisition of HistoSonics by an international consortium of technology and life sciences investors earlier this year. The new capital will be used to advance the commercialization of the Edison System, expand into new global markets, develop additional clinical indications such as kidney, pancreas, and prostate tumors, and scale operational infrastructure for rapid growth as a privately held company.
HistoSonics’ Edison System received FDA De Novo clearance in October 2023, marking a historic milestone for histotripsy. This therapeutic ultrasound-based technology uses focused sound energy to liquefy and destroy tumors with real-time imaging guidance. Unlike traditional surgical or radiation-based procedures, histotripsy is entirely non-invasive, avoids toxicity, and minimizes patient recovery time.
With the Edison System now clinically cleared for liver applications, the company’s next phase of expansion aims to make histotripsy a universal treatment modality for solid tumors and other diseases, reshaping the future of non-invasive medicine.
KEY QUOTES:
“This funding, which was a shared priority of our new ownership group, enables us to accelerate key projects designed to expand global access to our platform and advance our therapy across an unprecedented number of new clinical applications and for the patients who need it most.”
Mike Blue, Chairman and Chief Executive Officer, HistoSonics, Inc.
“Treatment decisions often force a trade-off between survival and suffering. HistoSonics shows that fundamental technological innovation can free us from such Faustian bargains. Beyond the focus today on abdominal tumors, the opportunity is to reimagine how a non-invasive approach could move treatment for other diseases earlier, alleviate the anxiety of monitoring, and preserve quality of life.”
Hannes Holste, Thiel Bio
“Histotripsy has the potential to redefine how we treat solid tumors and other diseases by introducing a completely new modality of care. HistoSonics’ Edison System combines breakthrough science, real-world clinical validation, and strong early commercial traction. We are proud to support and bolster the team as they accelerate adoption of this transformative technology.”
Bryan Baum, K5 Global
